The coronavirus; the pandemic that engulfs almost all parts of lives; the virus that allegedly dawned in China’s Wuhan province in the early November 2019. More than 55,502,641 infections have been reported and over 1,335,057 lives have been claimed. The data collected by ‘Worldometer’ started scoring the casualties when the ‘Red Dragon’ had registered its first such case in their country that later created ‘havoc’ in the whole world.
According to a nonprofit group working on vaccine allocation issues, the vaccine for the deadly virus would be available once it gets clearance from the US Disease Control and Prevention. Though it has not clarified the exact date or month for the official launch,the panel has said that the Covid shot would be available in the next 6-9 months. However, there are some mandatory criteria that the drug would have to pass during its clinical trial, but the expert panel said that many drugs have successfully passed most of the trail rounds.
According to the Associated Press, the vaccine will be injected on priority basis into those who have been involved in dealing with the deadly virus since the pandemic erupted last year. As per the US-based news agency, the vaccine would be first shot on health workers above 65 years.
According to the information available on the online platform of the indigenous Covid-19 vaccine manufacturer Covaxin, the company has received the approval of the Drugs Controller General of India (DCGI) for Phase I and II human clinical trials. These trials commenced across India in July, 2020.
“After the successful completion of the interim analysis from Phase 1 and 2 clinical trials of Covaxintm, Bharat Biotech received the DCGI approval for Phase 3 clinical trials for 26,000 participants at over 25 centres across India,” reads the ‘vaccine manufacturer’ website.